据国家医保局消息，包括石家庄四药在内的6家企业是在第七批国家组织药品集中采购品种盐酸溴己新注射液投标中存在串通申报、协商报价行为，违背在申报材料中作出的承诺，违反《全国药品集中采购文件（GY-YD2022-1）》有关条款。经前期约谈，成都欣捷、仁合益康、广州一品红、石家庄四药已退回医保资金损失，主动下调盐酸溴己新注射液价格，并另外选取3-4个药品主动降价。SSY Group (02005) fell by over 4%, as of the time of publication, it dropped by 4.21%, closing at HK$3.41, with a turnover of HK$5.3388 million.
According to the China Finance App, SSY Group (02005) fell by over 4%, as of the time of publication, it dropped by 4.21%, closing at HK$3.41, with a turnover of HK$5.3388 million.
On the news front, SSY Group announced last night that it was informed by the National Medical Products Administration that its wholly-owned subsidiary, Four Medicines in Shijiazhuang, was found to have violated the commitments and relevant provisions in the bidding for the tender of the hydrobromide bromohexine injection solution under the seventh batch of national centralized procurement of drugs, and its winning bid in the tender was cancelled; it was also included on the 'violation list' and has been suspended from participating in the national procurement for a period of six months from August 21, 2024 to February 20, 2025.
According to the National Healthcare Security Administration, including Four Medicines in Shijiazhuang, six companies were engaged in collusion in the bidding for the hydrobromide bromohexine injection solution under the seventh batch of national centralized drug procurement, violating the commitments made in the application materials and breaching the relevant provisions of the 'National Drug Centralized Procurement Document (GY-YD2022-1)'. Following prior consultations, Xinjie in Chengdu, Renheyikang, Yīpǐnhóng in Guangzhou, and Four Medicines in Shijiazhuang have refunded the losses of medical insurance funds, proactively reduced the price of the hydrobromide bromohexine injection solution, and voluntarily reduced the prices of an additional 3-4 pharmaceutical products.